Docebo (DCBO) EBITDA Margin (2019 - 2026)

Docebo (DCBO) has reported EBITDA Margin for 8 consecutive years, with 2.28% the latest figure, recorded in Q1 2026.

• Quarterly EBITDA Margin fell 526.0% year-over-year to 2.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 33.32% (up 2489.0% YoY) and the FY2025 annual result came in at 9.57%, down 24.0% from the prior year.
• EBITDA Margin declined to 2.28% in Q1 2026 per DCBO's latest filing, from 47.12% in the prior quarter.
• Over the last five years, EBITDA Margin for DCBO reached as high as 47.12% in Q4 2025 and fell as low as 21.43% in Q1 2022.
• A 5-year average of 11.41% and a median of 8.22% in 2024 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2023 — EBITDA Margin sank 2329 bps — and 2025, when it soared 3690 bps.
• Year by year, EBITDA Margin stood at 5.8% in 2022, then surged by 127 bps to 13.19% in 2023, then rose by 4 bps to 13.72% in 2024, then surged by 243 bps to 47.12% in 2025, then plunged by 105 bps to 2.28% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 2.28%, 47.12%, and 45.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.